Reyon Pharmaceutical이연제약
102460 · KOSPI · ₩102460 · 이연제약
₩9,720▼ ₩10 (0.10%)End-of-day · Oct 27, 2026 · End-of-day prices.
Filings
- Results of Rights Offering or Issuance of Equity-Linked Bonds, etc. (Voluntary Disclosure)유상증자또는주식관련사채등의발행결과(자율공시)Oct 28, 2026Open on DART
Predicted impact: Medium
Issue result of convertible bonds already decided and amended; size unknown, so lowered one level.
- Amended: Convertible bond issue decision[기재정정]주요사항보고서(전환사채권발행결정)Oct 27, 2026Open on DART
Predicted impact: Low
- Adjustment of Conversion Price, Warrant Exercise Price and Exchange Price (Informational Disclosure)전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)Oct 26, 2026Open on DART
Predicted impact: Low
Routine conversion price adjustment on convertible bond already disclosed in recent issue filings; no new shares by itself.
- Material Matters Report (Decision on Acquisition of Own Convertible Bonds Before Maturity)주요사항보고서(자기전환사채만기전취득결정)Oct 26, 2026Open on DART
Predicted impact: Low
Early buyback of own convertible bonds; size not given, likely reduces dilution overhang.
- 5%+ holding report주식등의대량보유상황보고서(약식)Oct 20, 2026Open on DART
Predicted impact: Low
- Adjustment of Conversion Price, Warrant Exercise Price and Exchange Price (Informational Disclosure)전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)Oct 16, 2026Open on DART
Predicted impact: Low· Actual: −6.1% vs sector, volume 1.3× normal (5 trading days)
Routine conversion price adjustment on convertible bond already disclosed in recent issue filings; no new shares by itself.
- Results of Rights Offering or Issuance of Equity-Linked Bonds, etc. (Voluntary Disclosure)유상증자또는주식관련사채등의발행결과(자율공시)Oct 16, 2026Open on DART
Predicted impact: Medium· Actual: −6.1% vs sector, volume 1.3× normal (5 trading days)
Issue result of convertible bonds already decided and amended; size unknown, so lowered one level.
- Amended: Convertible bond issue decision[기재정정]주요사항보고서(전환사채권발행결정)Oct 13, 2026Open on DART
Predicted impact: Low· Actual: −8.0% vs sector, volume 1.5× normal (5 trading days)
- Convertible bond issue decision주요사항보고서(전환사채권발행결정)Oct 8, 2026Open on DART
- Convertible bond issue decision주요사항보고서(전환사채권발행결정)Oct 8, 2026Open on DART
- 5%+ holding report주식등의대량보유상황보고서(일반)Oct 8, 2026Open on DART
- Change in largest shareholder's holdings최대주주등소유주식변동신고서Sep 28, 2026Open on DART
- 5%+ holding report주식등의대량보유상황보고서(일반)Sep 28, 2026Open on DART
- Material Matters Report (Decision on Acquisition of Own Convertible Bonds Before Maturity)주요사항보고서(자기전환사채만기전취득결정)Sep 28, 2026Open on DART
- Half-year report (Jun 2026)반기보고서 (2026.06)Aug 14, 2026Open on DART
- Disclosure of Corporate Governance Report기업지배구조보고서공시Jun 1, 2026Open on DART
- Quarterly report (Mar 2026)분기보고서 (2026.03)May 15, 2026Open on DART
- Annual general meeting results정기주주총회결과Mar 30, 2026Open on DART
- Report on Appointment, Dismissal, or Mid-Term Resignation of Independent Directors독립이사의선임ㆍ해임또는중도퇴임에관한신고Mar 30, 2026Open on DART
- Audit report submitted감사보고서제출Mar 20, 2026Open on DART
- Annual report (Dec 2025)사업보고서 (2025.12)Mar 20, 2026Open on DART
- Notice of Reason for Concentrated Shareholders' Meeting Date주주총회집중일개최사유신고Mar 12, 2026Open on DART
- Shareholders' meeting called주주총회소집결의Mar 12, 2026Open on DART
- Reference Document for Proxy Solicitation of Voting Rights의결권대리행사권유참고서류Mar 12, 2026Open on DART
- Notice of shareholders' meeting주주총회소집공고Mar 12, 2026Open on DART
- Change in revenue or profit of 30% or more매출액또는손익구조30%(대규모법인은15%)이상변경Feb 10, 2026Open on DART
- Quarterly report (Sep 2025)분기보고서 (2025.09)Nov 14, 2025Open on DART
- Adjustment of Conversion Price, Warrant Exercise Price and Exchange Price (Informational Disclosure)전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)Oct 27, 2025Open on DART
- Half-year report (Jun 2025)반기보고서 (2025.06)Aug 14, 2025Open on DART
- Amended: Annual report (Dec 2024)[기재정정]사업보고서 (2024.12)Aug 1, 2025Open on DART
- Adjustment of Conversion Price, Warrant Exercise Price and Exchange Price (Informational Disclosure)전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)Jul 25, 2025Open on DART
- 5%+ holding report주식등의대량보유상황보고서(약식)Jul 9, 2025Open on DART
- Amended: Quarterly report (Mar 2025)[기재정정]분기보고서 (2025.03)Jun 2, 2025Open on DART
- Quarterly report (Mar 2025)분기보고서 (2025.03)May 15, 2025Open on DART
- Adjustment of Conversion Price, Warrant Exercise Price and Exchange Price (Informational Disclosure)전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)Apr 25, 2025Open on DART
- Annual general meeting results정기주주총회결과Mar 28, 2025Open on DART
- Amended: Annual report (Dec 2024)[기재정정]사업보고서 (2024.12)Mar 24, 2025Open on DART
- Audit report submitted감사보고서제출Mar 20, 2025Open on DART
- Annual report (Dec 2024)사업보고서 (2024.12)Mar 20, 2025Open on DART
- Amended: Shareholders' meeting called[기재정정]주주총회소집결의Mar 14, 2025Open on DART
- [Attached Correction] Reference Documents for Proxy Solicitation for Exercise of Voting Rights[첨부정정]의결권대리행사권유참고서류Mar 14, 2025Open on DART
- [Amended] Reference Document for Proxy Solicitation of Voting Rights[기재정정]의결권대리행사권유참고서류Mar 14, 2025Open on DART
- Amended: Notice of shareholders' meeting[기재정정]주주총회소집공고Mar 14, 2025Open on DART
- Notice of Reason for Concentrated Shareholders' Meeting Date주주총회집중일개최사유신고Mar 13, 2025Open on DART
- Shareholders' meeting called주주총회소집결의Mar 13, 2025Open on DART
- Reference Document for Proxy Solicitation of Voting Rights의결권대리행사권유참고서류Mar 13, 2025Open on DART
- Notice of shareholders' meeting주주총회소집공고Mar 13, 2025Open on DART
- 5%+ holding report주식등의대량보유상황보고서(일반)Mar 12, 2025Open on DART
- Change in largest shareholder's holdings최대주주등소유주식변동신고서Feb 26, 2025Open on DART
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Feb 26, 2025Open on DART
Titles in Korean until English translations are added.
Also known as: Reyon Pharmaceutical / 이연제약 / 102460 / KRX:102460
Source: KRX statistical information